Global Onychomycosis (Tinea Unguium) Drug Market is expected to grow at a CAGR of XX% during the forecast period. The major factors driving the growth of this market are increasing awareness about onychomycosis, increasing number of patients with onychomycosis, and rising demand for nail care products. However, high cost associated with treatment and lack of awareness about onychomycosis are some factors that may hamper the growth of this market.
The global Onychomycosis (Tinea Unguium) Drug Market is segmented by type into oral medication, external medicine, and by application into age under 18 years old, age 150 years old or above 50 years old. The region-wise classification includes North America, Latin America, Europe, Asia Pacific and Middle East & Africa.
Some Of The Growth Factors Of This Market:
- Onychomycosis is a fungal infection of the nail bed and nail plate.
- The most common cause of onychomycosis is dermatophytes, which are fungi that live on the skin or in hair follicles and nails.
- Other causes include Candida, yeasts, and nondermatophyte molds such as Aspergillus and Cladosporium.
- The most common symptom of onychomycosis is thickening or discoloration of the toenails or fingernails.
- Onychomycosis can be treated with oral antifungal medications.
Industry Growth Insights published a new data on “Onychomycosis (Tinea Unguium) Drug Market”. The research report is titled “Onychomycosis (Tinea Unguium) Drug Market research by Types (Oral Medication, External Medicine, ), By Applications (Age under 18, Age 18-50, Age above 50, ), By Players/Companies Johnson and Johnson, GSK, Novartis, Pfizer, Valeant Pharma, Kaken Pharmaceutical, Galderma, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Onychomycosis (Tinea Unguium) Drug Market Research Report
By Type
Oral Medication, External Medicine,
By Application
Age under 18, Age 18-50, Age above 50,
By Companies
Johnson and Johnson, GSK, Novartis, Pfizer, Valeant Pharma, Kaken Pharmaceutical, Galderma, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
 Drug Industry Outlook.svg)
Global Onychomycosis (Tinea Unguium) Drug Market Report Segments:
The global Onychomycosis (Tinea Unguium) Drug market is segmented on the basis of:
Types
Oral Medication, External Medicine,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Age under 18, Age 18-50, Age above 50,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson and Johnson
- GSK
- Novartis
- Pfizer
- Valeant Pharma
- Kaken Pharmaceutical
- Galderma
- Xiuzheng Pharmaceutical
- Letai
- Qilu Pharmaceutical
 Drug Market Overview.svg)
Highlights of The Onychomycosis (Tinea Unguium) Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Medication
- External Medicine
- By Application:
- Age under 18
- Age 18-50
- Age above 50
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Onychomycosis (Tinea Unguium) Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drug Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Onychomycosis is a fungal infection of the nail. It can be caused by several different fungi, including Candida albicans and Trichophyton rubrum. Treatment typically involves using antifungal medications to kill the fungus and prevent it from growing further.
Some of the major players in the onychomycosis (tinea unguium) drug market are Johnson and Johnson, GSK, Novartis, Pfizer, Valeant Pharma, Kaken Pharmaceutical, Galderma, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Onychomycosis (Tinea Unguium) Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Onychomycosis (Tinea Unguium) Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Onychomycosis (Tinea Unguium) Drug Market - Supply Chain
4.5. Global Onychomycosis (Tinea Unguium) Drug Market Forecast
4.5.1. Onychomycosis (Tinea Unguium) Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Onychomycosis (Tinea Unguium) Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Onychomycosis (Tinea Unguium) Drug Market Absolute $ Opportunity
5. Global Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
5.3.1. Oral Medication
5.3.2. External Medicine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
6.3.1. Age under 18
6.3.2. Age 18-50
6.3.3. Age above 50
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Onychomycosis (Tinea Unguium) Drug Demand Share Forecast, 2019-2026
9. North America Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
9.4.1. Age under 18
9.4.2. Age 18-50
9.4.3. Age above 50
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
9.7.1. Oral Medication
9.7.2. External Medicine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Onychomycosis (Tinea Unguium) Drug Demand Share Forecast, 2019-2026
10. Latin America Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
10.4.1. Age under 18
10.4.2. Age 18-50
10.4.3. Age above 50
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
10.7.1. Oral Medication
10.7.2. External Medicine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Onychomycosis (Tinea Unguium) Drug Demand Share Forecast, 2019-2026
11. Europe Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
11.4.1. Age under 18
11.4.2. Age 18-50
11.4.3. Age above 50
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
11.7.1. Oral Medication
11.7.2. External Mdicine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Onychomycosis (Tinea Unguium) Drug Demand Share, 2019-2026
12. Asia Pacific Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
12.4.1. Age under 18
12.4.2. Age 18-50
12.4.3. Age above 50
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
12.7.1. Oral Medication
12.7.2. External Medicine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Onychomycosis (Tinea Unguium) Drug Demand Share, 2019-2026
13. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Application
13.4.1. Age under 18
13.4.2. Age 18-50
13.4.3. Age above 50
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size and Volume Forecast by Type
13.7.1. Oral Medication
13.7.2. External Medicine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Onychomycosis (Tinea Unguium) Drug Market: Market Share Analysis
14.2. Onychomycosis (Tinea Unguium) Drug Distributors and Customers
14.3. Onychomycosis (Tinea Unguium) Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Johnson and Johnson
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Valeant Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Kaken Pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Galderma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Xiuzheng Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Letai
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Qilu Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
